Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

Cognitive Study of Reactivity to IPH1101 of Peripheral γδ T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.

Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD, Philippe Rousselot, MD, Alexis Collette, Christine Paiva, Sophie Ingoure, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1530.

https://doi.org/10.1182/blood.V112.11.1530.1530

Published: 2008

Journal Articles

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Guy Laurent, MD, PhD, Jean François Rossi, MD, PhD, Eric W Van Den Neste, MD, PhD, Fabien Audibert, Hervé Ghesquières, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, Helene Sicard, PhD, Sophie Ingoure, Elodie Soule, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1002.

https://doi.org/10.1182/blood.V112.11.1002.1002

Published: 2008

Journal Articles

Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL

Jean François Rossi, MD, PhD, Valerie Rouillé, Sylvie Lafaye de Micheaux, MD, Hélène Sicard, PhD, Olivier Pétricoul, PhD, Lucile Beautier, Christine d’Arnoux, MD, Volker Kunzmann, MD, PhD

Blood (2008) 112 (11): 5011.

https://doi.org/10.1182/blood.V112.11.5011.5011

Published: 2008

Journal Articles

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Jean-Francois Rossi, PhD, MD, Julie Gertner, Helene Sicard, PhD, Guy Laurent PhD, MD, Sylvie Lafaye de Micheaux, MD, Jerome Tiollier, PhD, Jean-Jacques Fournie, PhD, Patrick Squiban, MD, Volker Kunzmann PhD, MD

Blood (2006) 108 (11): 5201.

https://doi.org/10.1182/blood.V108.11.5201.5201

Published: 2006

NARROW

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Cognitive Study of Reactivity to IPH1101 of Peripheral γδ T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Cognitive Study of Reactivity to IPH1101 of Peripheral γδ T Lymphocytes from Chronic Myeloid Leukemia, Multiple Myeloma and Follicular Lymphoma Patients.

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only